Department of Surgery, Hyperbaric Medicine, Amsterdam UMC, location AMC, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Radiat Oncol. 2022 Oct 6;17(1):164. doi: 10.1186/s13014-022-02067-6.
The aim of this study was to investigate the result of hyperbaric oxygen therapy (HBOT) in women with treated gynaecological malignancies who suffer from late radiation-induced tissue toxicity (LRITT). Moreover, which symptoms of LRITT benefit most from HBOT was evaluated as well.
An online literature search was conducted using PubMed; Embase and the Cochrane Library. Studies were included if the study examined gynaecological cancer patients who had been treated with radiotherapy, who suffered from LRITT and who subsequently received HBOT. In addition, the outcome measures were based on examining the effects of HBOT.
Twenty-one articles were included. The study investigating proctitis reported an improvement and three out of four studies investigating cystitis reported decreased complaints in women treated for gynaecological malignancies. In addition, all studies reported improvement in patients with wound complications and fifty percent of the studies reported better Patient Reported Outcome Measurements (PROMS) in women with gynaecological malignancies. Finally, all studies, except one related to pelvic malignancies reported reduced prevalence of symptoms for cystitis and proctitis and all studies reported better PROMS. However, only eleven studies reported p-values, nine of which were significant.
This study demonstrated that HBOT has a positive effect in women with gynaecological LRITT. Within the included patient group, gynaecological cancer patients with wound complications seem to benefit most from this treatment compared to other late side effects of LRITT.
本研究旨在探讨高压氧治疗(HBOT)对接受妇科恶性肿瘤治疗后出现晚期放射性组织毒性(LRITT)的女性的疗效。此外,还评估了 LRITT 的哪些症状最受益于 HBOT。
使用 PubMed、Embase 和 Cochrane Library 进行在线文献检索。如果研究检查了接受过放疗的妇科癌症患者,他们患有 LRITT 并随后接受 HBOT,则纳入研究。此外,研究结果是基于检查 HBOT 的效果。
共纳入 21 篇文章。研究直肠炎的文章报告了改善,研究膀胱炎的四分之三的文章报告了妇科恶性肿瘤治疗女性的投诉减少。此外,所有研究均报告了患有伤口并发症的患者有所改善,并且有 50%的研究报告了妇科恶性肿瘤患者的患者报告结局测量(PROMs)更好。最后,除了一项与盆腔恶性肿瘤相关的研究外,所有研究均报告了膀胱炎和直肠炎症状的发生率降低,并且所有研究均报告了更好的 PROMs。然而,只有 11 项研究报告了 p 值,其中 9 项具有统计学意义。
本研究表明,HBOT 对妇科 LRITT 患者具有积极影响。在纳入的患者群体中,与 LRITT 的其他晚期副作用相比,患有伤口并发症的妇科癌症患者似乎从这种治疗中受益最大。